BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinsons disease (PD)…
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Share this article
More News
Legal preparatory steps for crypto asset market
March 22, 2026
Pepeto Goes Viral While XRP Price Prediction
March 22, 2026
Crypto Horoscope from March 23 to 29, 2026
March 22, 2026
Crypto News This Week: Capital Continues Rotating Into
March 22, 2026